Song D, Zhang Z, Zheng J, Zhang W, Cai J
Biomark Res. 2025; 13(1):39.
PMID: 40055844
PMC: 11887266.
DOI: 10.1186/s40364-025-00751-9.
Nkonde K, Cheung S, Senn N, He J
Front Oncol. 2025; 15:1482112.
PMID: 39949748
PMC: 11821498.
DOI: 10.3389/fonc.2025.1482112.
Chia J, He G, Ngiam K, Hartman M, Ng Q, Goh S
Cancers (Basel). 2025; 17(2).
PMID: 39857979
PMC: 11764353.
DOI: 10.3390/cancers17020197.
Guo S, Wang D, Zhao Q, Bi Z, Li W, Zhu J
Quant Imaging Med Surg. 2025; 15(1):149-163.
PMID: 39839024
PMC: 11744159.
DOI: 10.21037/qims-24-511.
AlBuainain R, Bunajem F, Abdulla H
Eur J Breast Health. 2025; 21(1):46-51.
PMID: 39744907
PMC: 11706120.
DOI: 10.4274/ejbh.galenos.2024.2024-8-2.
Unlocking Chemotherapy Success: The Role of Diffusion Tensor Imaging in Breast Cancer Treatment.
Ciurea A, Bene I, Cheregi P, Brad T, Ciortea C, Rusu G
Diagnostics (Basel). 2024; 14(23).
PMID: 39682558
PMC: 11639939.
DOI: 10.3390/diagnostics14232650.
An explainable longitudinal multi-modal fusion model for predicting neoadjuvant therapy response in women with breast cancer.
Gao Y, Ventura-Diaz S, Wang X, He M, Xu Z, Weir A
Nat Commun. 2024; 15(1):9613.
PMID: 39511143
PMC: 11544255.
DOI: 10.1038/s41467-024-53450-8.
Deep-learning based discrimination of pathologic complete response using MRI in HER2-positive and triple-negative breast cancer.
Kim S, Lee J, Cho N, Kim Y
Sci Rep. 2024; 14(1):23065.
PMID: 39367159
PMC: 11452398.
DOI: 10.1038/s41598-024-74276-w.
Current status and prospects of breast cancer imaging-based diagnosis using artificial intelligence.
Sekine C, Horiguchi J
Int J Clin Oncol. 2024; 29(11):1641-1647.
PMID: 39297908
DOI: 10.1007/s10147-024-02594-0.
Comparison of radiomics-based machine-learning classifiers for the pretreatment prediction of pathologic complete response to neoadjuvant therapy in breast cancer.
Li X, Li C, Wang H, Jiang L, Chen M
PeerJ. 2024; 12:e17683.
PMID: 39026540
PMC: 11257043.
DOI: 10.7717/peerj.17683.
Utility of Axillary Staging in Older Patients with HER2-Positive Breast Cancer.
Dalton J, Crowell K, Ntowe K, van den Bruele A, DiNome M, Rosenberger L
Ann Surg Oncol. 2024; 31(11):7621-7633.
PMID: 39014162
PMC: 11452275.
DOI: 10.1245/s10434-024-15812-w.
The relationship between parameters measured using intravoxel incoherent motion and dynamic contrast-enhanced MRI in patients with breast cancer undergoing neoadjuvant chemotherapy: a longitudinal cohort study.
Almutlaq Z, Bacon S, Wilson D, Sharma N, Dondo T, Buckley D
Front Oncol. 2024; 14:1356173.
PMID: 38860001
PMC: 11163445.
DOI: 10.3389/fonc.2024.1356173.
Alginate-Chitosan Biodegradable and Biocompatible Based Hydrogel for Breast Cancer Immunotherapy and Diagnosis: A Comprehensive Review.
Patra P, Upadhyay T, Alshammari N, Saeed M, Kesari K
ACS Appl Bio Mater. 2024; 7(6):3515-3534.
PMID: 38787337
PMC: 11190989.
DOI: 10.1021/acsabm.3c00984.
Imaging evaluation of neoadjuvant breast cancer treatment: where do we stand?.
Alvarez-Benito M
Eur Radiol. 2024; 34(10):6271-6272.
PMID: 38753195
PMC: 11399156.
DOI: 10.1007/s00330-024-10799-0.
Enhancing pathological complete response prediction in breast cancer: the role of dynamic characterization of DCE-MRI and its association with tumor heterogeneity.
Zhang X, Teng X, Zhang J, Lai Q, Cai J
Breast Cancer Res. 2024; 26(1):77.
PMID: 38745321
PMC: 11094888.
DOI: 10.1186/s13058-024-01836-3.
Evaluating persistent T1-weighted lesions without concurrent abnormal enhancement on breast MRI in neoadjuvant chemotherapy patients: implications for complete pathological response.
Goulam-Houssein S, Ye X, Fleming R, Au F, Kulkarni S, Ghai S
Eur Radiol. 2024; 34(10):6273-6282.
PMID: 38491128
DOI: 10.1007/s00330-024-10695-7.
Automated and reusable deep learning (AutoRDL) framework for predicting response to neoadjuvant chemotherapy and axillary lymph node metastasis in breast cancer using ultrasound images: a retrospective, multicentre study.
You J, Huang Y, Ouyang L, Zhang X, Chen P, Wu X
EClinicalMedicine. 2024; 69:102499.
PMID: 38440400
PMC: 10909626.
DOI: 10.1016/j.eclinm.2024.102499.
A Diagnostic Dilemma: New Enhancing Suspicious Findings on Breast MRI Following Neoadjuvant Chemotherapy.
LaRoy J, Tadros A, Sevilimedu V, Mango V
J Breast Imaging. 2024; 5(4):453-458.
PMID: 38416906
PMC: 11166475.
DOI: 10.1093/jbi/wbad035.
Prediction of pathological complete response of breast cancer patients who received neoadjuvant chemotherapy with a nomogram based on clinicopathologic variables, ultrasound, and MRI.
Zhang M, Liu X, Du Y, Zha H, Zha X, Wang J
Br J Radiol. 2024; 97(1153):228-236.
PMID: 38263817
PMC: 11027305.
DOI: 10.1093/bjr/tqad014.
A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer.
Lopez-Velazco J, Manzano S, Otano M, Elorriaga K, Bulto N, Herrero J
Breast Cancer Res. 2024; 26(1):3.
PMID: 38173005
PMC: 10765775.
DOI: 10.1186/s13058-023-01756-8.